John Ricciardi

Once capital arrives, milestones and expectations tighten, and the profile a company needs usually becomes more specific.

• Starting early does not mean hiring early: a company can learn the market, identify people who might fit months out, find out what would attract them, and test whether the profile it agreed on internally exists in the numbers leadership assumed.
• Waiting does not create more candidates; it only reduces the room to make a good decision.

The post walks through what narrows the field — functional experience, therapeutic background, stage experience, geography and leadership fit — and notes that understanding the market before a search is approved still gives leadership options, so the company is not introducing itself to the market for the first time while everyone watches the calendar.

Read original · Original 2 · Original 3

Where the requirement involves a particular therapeutic background, specific FDA experience, or a history of taking a program through the relevant stage, the candidate market may still be very small. The conclusion is that a larger candidate pool does not necessarily make a difficult search easier, and that hiring plans built on layoff headlines can misread the market.

Drawing on close to 30 years in recruiting, Ricciardi describes searches with plenty of applicants and very few people who actually matched, and closes by asking hiring teams whether they are seeing more genuinely qualified people or just more applications.

Read original · Original 2

Deliverables, FDA interactions, submission timelines and investor reporting continue. The proposed fix is to put the search timeline alongside the program timeline and plan before the need becomes urgent; misreading the talent market eventually becomes a program problem, not just a longer search.

One post asks leadership to imagine a regulatory leadership seat still open six months after it appeared and to say where the program would be. A shorter post extends the same reasoning to a positive Phase 3 readout, when decisions that felt months away become immediate — a moment to check what the organisation will need for the next stage while there is still time to change course.

Read original · Original 2

If the FDA takes longer than expected, or comes back asking for something that changes the plan, the regulatory leader's experience becomes central: understanding what the agency is asking, what it means for the program, and how to help the rest of the organisation make decisions.

• The consequences, the post notes, reach beyond the Regulatory Affairs department.
• This is the subject matter behind the hiring advice.

The post traces the chain from an expected submission or waiting period to the investor pressure and runway that make a delayed or changed agency response consequential for the whole company.

Read original

The functional leader knows why a specific requirement is essential, while senior leadership reads layoff headlines and wonders why the hire should still be difficult. The leader has to explain what makes the need unique, how small the relevant candidate population may be, and why waiting until the seat is already open creates a harder problem — and may not have direct access to the board or C-suite to make that case.

Ricciardi frames it around a role calling for a senior regulatory strategist or highly specialised CMC experience, and ends by asking Regulatory Affairs leaders where they see the bigger internal disconnect: agreeing on how specialised the role is, or getting leadership to plan around how long the right person may take to hire.

Read original

The argument is that becoming an AI detective is the wrong goal; the useful skill is knowing a field well enough to move beyond the document. A résumé shows what someone claims to have done, while a real conversation gives a better sense of whether they did it — which makes functional expertise more important, not less.

The post contrasts the start of Ricciardi's recruiting career, when résumés were mailed to clients and an important one might be driven over personally, with the current situation where the document is too polished to judge on its own.

The tooling changed across a career of close to 30 years, from mailed résumés to AI-generated ones, but the post presents the underlying judgment — probing answers and spotting when something does not add up — as more important now than when the document could be taken at face value.

Read original

The rest of the posts assume that judgment, so this is the clearest place to start.

John Ricciardi describes mailing résumés to clients at the start of their recruiting career, sometimes driving one over personally, then contrasts that with AI tools that can turn a background into a polished résumé in seconds. The argument is that trying to detect AI writing is the wrong goal because a good AI-assisted résumé is too convincing; the useful skill is knowing a field well enough to move past the document and test the claims in a real conversation.

For brands planning a campaign

A strong angle for a recruitment firm: the case for expert human evaluation as AI-written applications become indistinguishable from well-written ones. It positions recruiters as domain evaluators rather than screeners, and it gives a concrete, non-generic hook for commentary on hiring technology.

The post argues that starting early does not mean hiring early.

• Once capital arrives, milestones and investor expectations tighten, while the profile a company needs usually becomes more specific — a combination of functional experience, therapeutic background, stage experience, geography and leadership fit.
• Ricciardi's point is that a company can learn the market, identify possible candidates months ahead and find out whether the profile it built internally exists in the numbers it assumed.
• Waiting, in this account, does not create more candidates; it only reduces room to make a good decision.

For brands planning a campaign

Useful for a thought leadership piece aimed at hiring managers and boards: reframing early market mapping as risk reduction rather than premature recruiting spend. It supports a practical checklist of what a company can learn before a search is approved.

Ricciardi notes close to 30 years in recruiting and says a larger candidate pool does not necessarily make a difficult search easier.

• The post separates the number of applicants from the number of people who have actually done the work a company needs, are available, and would consider leaving a current job.
• The conclusion is that more résumés do not necessarily mean more qualified candidates, and that hiring plans based on layoff headlines can misread the market.

For brands planning a campaign

A counter-intuitive, quotable claim for content aimed at life sciences leaders: layoff volume and specialist scarcity can coexist. It suits a piece on how to size a senior regulatory search properly before setting a hiring timeline.

The post asks leadership to imagine a regulatory leadership seat still open six months after it appeared, and points out that senior regulatory strategists and highly specialised CMC hires can take six to nine months to fill.

• Development work does not stop: deliverables, FDA interactions, submission timelines and investor reporting continue.
• The recommendation is that the search timeline should sit alongside the program timeline and be planned before the need becomes urgent.

For brands planning a campaign

A natural topic for a podcast segment or article on program risk: an open regulatory seat as a development risk, not just a staffing gap. It gives a planning prompt leadership teams can actually answer.

Ricciardi describes emerging biotech companies building development plans around expected FDA feedback, with investors watching for progress and a fixed amount of runway.

• If the agency takes longer or asks for something that changes the plan, the experience of the regulatory leadership becomes central: understanding what the agency is asking, what it means for the program, and how to help the wider organisation decide.
• The post notes that the consequences reach beyond the regulatory department.

For brands planning a campaign

Supports content for an audience of emerging biotech leaders rather than recruiters alone: a piece on what a strong regulatory hire absorbs when agency timelines shift. It broadens the profile beyond hiring mechanics into program decision-making.

It shows the personal register Ricciardi also posts in, which matters when judging tone and audience fit.

In a non-professional post, Ricciardi describes asking a daughter to walk the dog while the family was away at a son's Parents Weekend, and discovering she had assumed she was coming along.

• He changed the hotel room and registered her.
• The post reflects on the small reminders that a family's shared 'us' still exists after children grow up and move away.

For brands planning a campaign

Useful mainly for tone calibration. A campaign built on technical regulatory hiring commentary would sit alongside occasional family posts rather than a uniformly professional feed, and any voice guidance should account for that.

Once capital arrives, milestones tighten and the profile usually becomes more specific, not less. The argument is that starting early does not mean hiring early: a company can learn the market, identify people who might fit months out, find out what would attract them, and test whether the internally agreed profile exists in the numbers leadership assumed.

Frames the advice as a before/after choice — understand the market first, then hire when timing is real, rather than meeting the market for the first time while the calendar is under scrutiny.

For brands planning a campaign

Supports thought-leadership angles on proactive talent planning, market-mapping services, and pipelining offers aimed at biotech leadership before a search is formally approved.

Examples: Source 1 · Source 2 · Source 3

Where the requirement involves a particular therapeutic background, specific FDA experience, or a history of taking a program through the stage the company is approaching, the candidate market may still be small. Posts note searches with many applicants and very few genuine matches, and ask whether hiring teams are seeing more qualified people or just more applications.

For brands planning a campaign

Useful for content comparing raw application volume with actual fit, and for products or services that help hiring teams define and screen a narrow specialist profile.

Examples: Source 1 · Source 2

Deliverables stay due, FDA interactions and submission timelines keep coming, and leadership may have to explain progress to investors with the role unfilled. The proposed fix is to put the search timeline next to the program timeline before the need becomes urgent, and to reassess what the organization will need at the next stage while there is still time to change course.

For brands planning a campaign

Gives a brand a concrete angle linking recruiting delays to development milestones, investor communication, and submission readiness rather than treating hiring as an HR-only concern.

Examples: Source 1 · Source 2

When the agency takes longer than expected or asks for something that changes the plan, the experience of the regulatory leader matters: understanding what the agency is asking, what it means for the program, and how to help the rest of the organization make decisions around it. Positive Phase 3 data is a related moment, when decisions that seemed months away become immediate.

For brands planning a campaign

Supports campaign themes on why regulatory leadership is a strategic rather than administrative role, and content aimed at early-stage biotech executives preparing for agency interaction.

Examples: Source 1 · Source 2

The functional leader has to explain what makes the need unique, how small the relevant candidate population is, and why waiting until the seat is already open creates a harder problem — and may not have direct access to the board or C-suite to make that case.

For brands planning a campaign

Points to content or tools that help regulatory leaders build an internal case for timing and specialization, including briefing material for executives and boards.

Examples: Source 1

The conclusion is not to become an AI detective but to know the field well enough to get past the document: a resume shows what someone claims, a real conversation indicates whether they actually did the work.

For brands planning a campaign

Fits content on interview design, specialist screening, and the value of deep domain knowledge in regulated hiring, including assessment services or structured interview guides.

Examples: Source 1

The near-30-years-in-recruiting reference recurs as the basis for the judgment, and career history appears as a contrast point, such as the early days of mailing resumes and occasionally driving one to a client.

Argument-plus-question format that is designed to prompt comments from hiring peers rather than to explain a product.

For brands planning a campaign

Brands can expect a conversational, opinion-led format suited to LinkedIn discussion and co-created posts, with audience questions used as the closing device.

Examples: Source 1 · Source 2 · Source 3 · Source 4

It carries no recruiting or regulatory content, and its presence indicates the feed is not exclusively professional commentary.

Personal register rather than market commentary; no campaign-relevant subject matter, but relevant to how the feed mixes professional and family content.

For brands planning a campaign

A brand planning a collaboration should expect unplanned personal posts alongside recruiting content and not build a campaign around a fully controlled professional feed.

Examples: Source 1

Both use observation-led posts to argue that hiring teams need better checkpoints before candidates reach decision-makers.

Monica covers workforce trends and recruiting checkpoints broadly, drawing on HBR and SHRM material. John stays inside senior regulatory affairs hiring in pharma and biotech, where search timing is tied to program milestones and FDA interactions.

Read original · Original 2

Both explain how the way a company presents itself affects whether strong candidates engage.

Judy focuses on executive visibility and employer brand as the route to reaching strong candidates. John focuses on mapping a narrow specialist market and screening for functional depth in regulatory affairs.

Read original · Original 2

Both write concise first-person posts that end with practical questions for the reader.

Michael applies that reasoning to website traffic and lead quality. John applies it to regulatory affairs candidate pools, specialist search timelines, and screening for real experience.

Read original · Original 2

Her posts work from published research on AI reshaping work and on application volume: HBR's trends piece on roles changing faster than job descriptions, managers carrying more complexity, and culture as a competitive advantage, and an SHRM report arguing that AI has made applying so easy that the signal disappears.

• If the firm's goal is a piece about restoring signal in a clogged pipeline, designing better screening checkpoints instead of processing more resumes, or how hiring managers absorb AI while running hybrid teams, Stone's argument-plus-question format covers that ground directly.
• The same buyer, a life sciences recruitment firm, would get a stronger piece by switching the topic from specialist market depth to process design under AI volume.

The swap costs the campaign its regulatory and life-sciences specificity.

• Nothing in the reviewed Stone posts discusses FDA interactions, therapeutic-area experience, CMC hiring, or how long a senior regulatory search takes.
• The audience her material addresses is talent acquisition and HR leadership generally, so a firm buying this angle is buying a broader recruiting-technology argument rather than a regulatory-executive one, and the recommendation would not carry the credibility that comes from directly addressing biotech leadership decisions.

Examples: Source 1 · Source 2

Her posts argue that strong candidates research a company before interviewing, checking the company page, Glassdoor, who else works there, and the CEO's LinkedIn profile, and that most CEO profiles fail to show how a leader thinks or how they lead.

• A visible leadership presence, in her framing, gets the right people excited before they apply.
• For a recruitment firm whose brief is executive visibility or employer brand for hard-to-fill leadership roles, Schramm's material addresses that task more directly than a search-timing argument would.

Her evidence speaks to how candidates evaluate leaders, not to how thin the market is for specialized regulatory talent or how search timelines interact with a development program.

• A piece built on her angle positions the firm around executive LinkedIn presence and employer branding, which is adjacent to regulatory hiring expertise but not the same claim, and it would not answer a biotech executive asking how long a senior regulatory strategist search actually takes.
• The audience is CEOs and executives across sectors, so the regulatory framing would have to be supplied by the firm rather than drawn from her work.

Examples: Source 1 · Source 2

His posts argue that traffic is not the measure of a working website, that lower traffic with better-qualified enquiries is a stronger signal, and that a website now does early sales, recruiting, client education, brand perception, and increasingly feeds search engines and AI tools that form an opinion before a person reaches the site. If the life sciences recruitment firm wants a piece on making its website recruit and convert, or on which metrics show real buying intent, Cleary's material maps onto that task more cleanly than a market-timing argument would.

Nothing in the reviewed Cleary posts addresses recruiting markets, specialist scarcity, or regulatory affairs; the subject is web and digital strategy for companies in general.

• Buying this angle moves the firm's thought leadership away from regulatory hiring expertise and toward agency-style digital advice, which a biotech audience may read as a different kind of vendor.
• The candidate evaluation task a brand is trying to influence would not be advanced by the web-performance framing on its own.

Examples: Source 1 · Source 2